Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of EYP-1901 versus aflibercept for wet age-related macular degeneration
MOH_2025-01-26_013871Phase 3Not yet recruiting
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Dec 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing EYP-1901 arm with Aflibercept arm (2 arms). Planned start Dec 2024; status: not yet recruiting.
02
Drugs
vorolanibaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2025-01-26_013871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-26_013871.